IBS is conducting clinical trials of AstraZeneca-Oxford’s COVID-19 vaccine in India. (Representative)
New Delhi:
The leading Serum Institute of India for vaccines said Thursday that the COVID-19 vaccine developed by AstraZeneca and the University of Oxford is safe and effective, and that Indian trials are progressing smoothly with strict adherence to all protocols.
The comments came after AstraZeneca and the University of Oxford acknowledged a manufacturing error that is raising questions about the preliminary results of its experimental COVID-19 vaccine.
A statement describing the error came days after the company and the university described the injections as “highly effective” and failed to mention why some study participants did not receive as much vaccine in the first of two injections as expected.
Asking people to be patient and not panic, the Serum Institute of India (SII) said in a statement: “The AstraZeneca-Oxford vaccine is safe and effective. Even the lowest efficacy results are 60-60. 70%, which makes it a viable vaccine. ” against the virus “.
With that said, varied age groups with different dosage forms will result in slight variations and efficacy. “We must be patient and not panic,” he added.
IBS is conducting clinical trials of AstraZeneca-Oxford’s COVID-19 vaccine candidate in India.
“The Indian trials are running smoothly with strict adherence to all necessary processes and protocols. So far, there are no concerns. However, we are reviewing the data that is available and will make further statements, if necessary,” said SII. .
Earlier this week, AstraZeneca said that an interim analysis of clinical trials of its COVID-19 vaccine in the UK and Brazil showed it to be 70 percent effective on average, becoming the third drugmaker to announce promising results for contain the deadly virus.
The company also said the vaccine, developed with the University of Oxford, showed 90% efficacy in one dosing regimen when the vaccine was given as a half dose, followed by a full dose at least a month later, while in another. dosage regimen. showed 62 percent efficacy when given in two full doses at least one month apart.
“The combined analysis of both dosing regimens resulted in an average efficacy of 70 percent,” he had said.
(This story has not been edited by NDTV staff and is automatically generated from a syndicated feed.)
.
